Edgewise Therapeutics, Inc. EWTX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s stock issuance proceeds?
- Edgewise Therapeutics, Inc. (EWTX) reported stock issuance proceeds of $12.17M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Edgewise Therapeutics, Inc.'s stock issuance proceeds increased by 438.4% year-over-year, from $2.26M to $12.17M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s stock issuance proceeds?
- Over 2 years (2021 to 2023), Edgewise Therapeutics, Inc.'s stock issuance proceeds has grown at a 2067.5% compound annual growth rate (CAGR), from $112K to $52.62M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.